biostudies-literatureUnknown8(5)Tivey A<h4>Abstract</h4>During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving ibrutinib with or without rituximab for untreated MCL were evaluated for treatment toxicity, response, and survival, including outcomes in high-risk MCL (TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, or Ki67 ≥ 30%). A total of 149 patients from 43 participating centers were enrolled: 74.1% male, median age 75 years, 75.2% Eastern Cooperative Oncology Group status of 0 to 1, 36.2% high-risk, and 8.9% autologous transplant candidates. All patienBlood advances1209-1219https://www.ebi.ac.uk/biostudies/studies/S-EPMC10912842biostudies-literatureIbrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.PMC10912842Fowler NDukka VGoddard JRees CSharpley FSantarsieri AWilson JProtheroe STalbot GWilson MLambert JWrench DCrosbie NSwe WMoule SKnott COwen MPillai AEdiriwickrema KSutton TWright JMohamedbhai SWalter HPrahladan MChaturvedi AStern STivey AQureshi IFlont MNga EWillimott VBailey JEverden ADavies ELewis DMiall FJones SBishton MMcCulloch RTucker DBurney CReeve MThomas NStanton LZhao RNorman JVirchis AJackson BMaddox JHildyard CBeech AEyre TALowry LCamacho RGHodson AAllchin RShotton RMarr HPhillips NKoppana MNicholson TPaneesha SBedford CSmith SLord AWebb AGibb ALinton KfalseIbrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.<h4>Abstract</h4>During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving ibrutinib with or without rituximab for untreated MCL were evaluated for treatment toxicity, response, and survival, including outcomes in high-risk MCL (TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, or Ki67 ≥ 30%). A total of 149 patients from 43 participating centers were enrolled: 74.1% male, median age 75 years, 75.2% Eastern Cooperative Oncology Group status of 0 to 1, 36.2% high-risk, and 8.9% autologous transplant candidates. All patien2024-01-01T00:00:00Z2024 Mar2026-06-17T06:31:33.138Z2026-06-17T03:06:56.198ZS-EPMC109128423812727910.1182/bloodadvances.2023011152